Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial – The Lancet Commentaries: Heterologous vaccine regimens against COVID-19 – The Lancet AND   Commentary on Twitter (thread – click for more) NEW #COVID19 research—Phase 2 trial by @borobia_am, @antoniojcarcaset al. reports BNT162b2 given as a 2nd […]

The post Phase 2 RCT: Immunogenicity and reactogenicity of a Pfizer-BioNTech booster in patients that have received a single dose of AstraZeneca vaccine – “BNT162b2 (Pfizer) given as a second dose in individuals prime vaccinated with ChAdOx1-S (AstraZeneca) induced a robust immune response, with an acceptable and manageable reactogenicity profile”. appeared first on Links Medicus.